Boston expands endoscopy offerings:
This article was originally published in Clinica
Executive Summary
Boston Scientific has bought a range of new endoscopic stent technologies, designed to treat gastrointestinal and airway obstructions, from Teleflex Medical subsidiary Willy Rusch. Financial details of the agreement were not disclosed. The acquired portfolio includes the Polyflex line of oesophageal and airway stents - currently distributed in the US by Boston Scientific under a previous agreement with Rusch - as well as the Y Dynamic tracheo-bronchial stent. Rusch will continue to distribute these products in Europe through to the end of 2005. Patients with oesophageal obstructions have difficulty eating and swallowing and could also suffer life-threatening interferences to their normal breathing. Endoscopic stenting is a less-invasive procedure in which a stent is inserted through an endoscope into the oesophagus, trachea or bronchial tubes to maintain the natural opening.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.